Were always happy to geek out over a buzzyskin careingredient when we see it making the rounds on product labels. (See: lactic acid, rosehip oil, bakuchiol) So when we started noticing the proliferation of niacinamide, we were surprised to learn that not only has it been around for a while buttheres a decent body of research behind the multipurpose vitamin. Heres what you need to know about niacinamidesbenefits for your skin.

Niacinamide, a form of vitamin B3 also known as nicotinamide, is a water-soluble vitamin that has potent antioxidant activity and reduces inflammation, saysboard-certified dermatologistDavid Lortscher, CEO of Curology.

It would be an exaggeration to call niacinamide a cure-all, but it does have a pretty extensive range when it comes to the conditions it can treat: acne, oil regulation, fine lines and wrinkles, hyperpigmentation, enlarged pores and sun damage. Its especially good at repairing skins moisture barrier (aka its first line of defense) and protecting against environmental stressorsits even been shown to help prevent skin cancer in certain studies.

Niacinamides nourish and calm redness and inflammation,says DendyEngelman, a board-certified dermatologist in New York. She particularly likes niacinamide for dry and sensitive skin: It has similar effects to retinol by strengthening the skin barrier, but itfortifies from the get-go without sensitivity or irritation.Dr. Lortscher also has high praise: Because of its role in repairing the skin barrier, niacinamide is one of the most effective treatments for photoaging [damage caused by UV rays], according to most anti-aging research.

It starts to get technical here, but as Dr. Engelman explains it, Niacinamide helps support the cellsmetabolic system, specifically fibroblasts. We use fibroblasts tomake and repair DNA,which,in turn, activates collagen production. So by using niacinamides to boost fibroblast production, we are supporting collagen production and repairing damaged collagen.

Lots of products contain niacinamideserums, moisturizers, even cleansersand it works well in conjunction with other active ingredients, like retinol. It can be used both morning and night, though as with any goodskin careregimen, you should follow it up with a sunscreen during the day.

Niacinamide should be compatible with most otherskin careproducts and is well tolerated by all skin types,including sensitiveskin, Dr. Lortscher says. For best results, use leave-on products with niacinamide. Its safe to use around the eyes, anditmay improve the appearance of under-eye darkness and wrinkles.

Convinced yet? Check out a few of our favorite products containing the powerhouse ingredient below.

RELATED: We Ask a Derm: What Ingredients Should You Avoid If You Have Oily Skin?

Of course, the uber-popular, wallet-friendly brand is on top of it. This serum is especially helpful for congested, acne-prone skin: The niacinamides anti-inflammatory propertiescalm active breakouts, while its oil-regulating properties (and the addition of zinc, which also keeps oil in check) help keep new ones from forming.

Buy it ($6)

Nia 24 uses a patented form of niacinamide thats designed to absorb better into skin (and therefore work its magic more effectively). This rich cream strengthens the skin barrier with its namesake ingredient, plus hyaluronic acid, licorice root extract, peptides and ceramides.

Buy it ($118)

Give parched, dull skin a quick pick-me-up with a five-star-rated gel sheet mask. Reviewers rave about its glow-inducing, hydrating properties and the fact that its gentle enough for sensitive skin.

Buy it ($3)

Cursed by the ghosts of pimples past? Niacinamide, glycolic acid and NASA-developed plant stem cells (!) work together to combat hyperpigmentation and scarring.

$20 on Amazon

Derms, dry-skinned gals and makeup lovers alike know oil cleansers are a godsend forwashing off the days makeup withoutstripping any precious natural moisture. This cleanser amps up the effects with niacinamides barrier-strengthening effects, plus offers a gentle exfoliation thanks to fruit enzyme.

Buy it ($42)

SkinCeuticals serums are cult faves for a reason, and this 5 percent niacinamide serum is no exception. Its amped up with amino acids, algae extract and peptides to target the effects of environmental stress and promote collagen production.

Buy it ($112)

RELATED: The Best Face Moisturizer for Dry, Sensitive Skin, According to People Who Use Them

Read this article:
Heres How Niacinamide Benefits Your Complexion (and How to Work It into Your Skin Care Routine) - Yahoo Lifestyle

Skin Stem Cells Comments Off on Heres How Niacinamide Benefits Your Complexion (and How to Work It into Your Skin Care Routine) – Yahoo Lifestyle | December 1st, 2019

The most raved about secret in beauty this year wasn't a magic facialist or Real Housewife-lauded injection, it was an unassuming moisturizer made by a 60-year-old German scientist who'd never worked in the industry, let alone had an Instagram following. And yet, despite having none of the traditional resources that makes a beauty brand an overnight successlike paid celebrity spokespeople, $1 million ad campaigns, or millennial pink packagingAugustinus Bader became a sleeper hit purely through word of mouth.

In the nearly two years since it launched, AB's "miracle cream" has gotten accolades from Ashley Graham, Kate Bosworth, and Victoria Beckham (who's since launched a moisturizing primer with the brand). Glamour even gave it a Beauty Award for Best Moisturizer, a highly competitive category as you can surely imagine. So before I even uncapped the weighty blue-and-copper tube of its famed The Cream, which costs a cool $265 for 50 mL, I was basically set to fall in love with itprice tag be damned.

But the only kind of hype I pay real attention to is beauty editor hype; if my product-inundated colleagues are raving about it, I figure it has to stand out from the pack. And for weeks, every single editor I knew had told me about the cream in an attitude I can only describe as reverent. I was ready to experience my own Bader-sparked miracle.

Bizarrely, I didn't immediately fall head over heels for it (don't worry, a second plot twist will follow shortly). Sure, it was a good face cream. The light texture absorbed quickly and my skin looked decent, but it didn't exactly wow me. I felt like a thin layer just wasn't doing much in the moisturizing departmentwhich, apparently, I later learned isn't even what The Cream claims to do. It's more of an overall skin rejuvenator. The brand also sells a Rich Cream for dry skin, which contains additions like avocado and argan oil to aide with extra hydration, but I began with the original thinking it'd be enough.

In order to get maximum effectiveness from the active ingredients, I did what a few other friends and makeup artists had advised and skipped all other products, except face wash. The Bader formula is based on TFC8 (Trigger Factor Complex 8), a proprietary cocktail of over 40 different ingredients, including vitamins and amino acids. It's meant to encourage regeneration and healingProfessor Bader actually discovered the formula while looking for solutions to help burn survivors heal quickerand TFC8 is supposed to activate your stem cells, which go to work to repair fine lines, dark spots, and visible pores. I had heard that the ingredients within were enough to replace all other skin care, so I devoted myself to a one-step kind of lifestyle and waited for my skin to start looking like I had just walked out of a spa. And then I waited some more...

Read the original here:
Augustinus Bader The Cream Review: Why It's Worth Every Cent - Glamour

Skin Stem Cells Comments Off on Augustinus Bader The Cream Review: Why It’s Worth Every Cent – Glamour | November 29th, 2019

Birds of a feather may flock together, but the feathers of birds differ altogether.

New research from an international team led by USC scientists set out to learn how feathers developed and helped birds spread across the world. Flight feathers, in particular, are masterpieces of propulsion and adaptation, helping penguins swim, eagles soar and hummingbirds hover.

Despite such diversity, the feather shares a common core design: a one-style-fits-all model with option trims for specialized performance. This simplicity and flexibility found in nature holds promise for engineers looking for better ways to build drones, wind turbines, medical implants and other advanced materials.

Those findings, published today in Cell, offer an in-depth look at the form and function of a feather based on a comparative analysis of their physical structure, cellular composition and evolution. The study compares feathers of 21 bird species from around the world.

Weve always wondered how birds can fly in so many different ways, and we found the difference in flight styles is largely due to the characteristics of their flight feathers, said Cheng-Ming Chuong, the studys lead author and a developmental biologist in the Department of Pathology at the Keck School of Medicine of USC. We want to learn how flight feathers are made so we can better understand nature and learn how biological architecture principles can benefit modern technology.

To gain a comprehensive understanding of the flight feather, Chuong formed a multi-disciplinary international team with Wen Tau Juan, a biophysicist at the Integrative Stem Cell Center, China Medical University in Taiwan. The work involved experts in stem cells, molecular biology, anatomy, physics, bioimaging, engineering, materials science, bioinformatics and animal science. The bird species studied include ostrich, sparrow, eagle, chickens, ducks, swallow, owl, penguin, peacock, heron and hummingbird, among others.

They compared feathers using fossils, stem cells and flight performance characteristics. They focused on the feather shaft, or rachis, that supports the feather much like a mast holds a sail, bearing the stress between wind and wing. They also focused on the vane, the lateral branches astride the shaft that give the feather its shape to flap the air. And they examined how evolution shaped the barbs, ridges and hooks that help a feather hold its form and lock with adjacent feathers like Velcro to form a wing. The goal was to understand how a simple filament appendage on dinosaurs transformed into a three-level branched structure with different functions.

We want to learn how flight feathers are made so we can better understand nature and learn how biological architecture principles can benefit modern technology.

Cheng-Ming Chuong

For birds such as ducks, eagles and sparrows that fly in different modes, the scientists noted significant differences in the feather shaft compared to ground-hugging birds. On the rigid exterior, the shaft cortex was thinner and lightweight, while the interior was filled with porous cells resembling bubble wrap, aligned into bands of various orientations and reinforced with ridges that operate like tiny lateral beams. Together, it forms a light, hollow and buoyant structure to enable flight. Cross-sections of feather shafts of different birds show highly specialized shapes and orientations of the inner core and outer cortex.

The flight feather is made of two highly adaptable architectural modules, light and strong materials that can develop into highly adaptable configurations, Chuong said.

The researchers discovered two different molecular mechanisms guiding feather growth. Cortex thickness was governed by bone morphogenetic proteins, which are molecular signals for tissue growth. The porous feather interior, or medulla, relied upon a different mechanism known as transforming growth factor-beta (TGF-b). Both components originate as stem cells in the birds skin.

By contrast, feathers in flightless birds were simpler, consisting of a dense cortex exterior that is more rigid and sturdy with fewer internal struts and cells found in flying birds. The features were especially pronounced for penguins, which use wings as paddles under the water.

As part of the study, the researchers looked at 100 million-year-old feathers, found embedded in amber in Myanmar. These fossils show early feathers lacked one key feature that modern birds have. Specifically, the researchers report that fossil feathers had barb branches and barbules, which form a feather vane by overlapping, but not hooklets. The hooklets, which act like clasps to turn fluffy feathers into a tight flat plane for high-performance flight, evolved later. The scientists also identified WNT2B, another growth factor, as the agent that controls hooklet formation. These also originated from epidermal stem cells.

Taken together, the findings show how feathered dinosaurs and early birds could form a primitive vane by overlapping barbule plates, although that wasnt aerodynamically fit to carry much load. As more complex composite features occurred in the wing, it got heavier, so feather shafts became stronger yet more lightweight, which led to stiffer feathers and sturdy wings that powered flight to carry birds around the world.

Our findings suggest the evolutionary trends of feather shaft and vane are balanced for the best flight performance of an individual bird and become part of the selective basis of speciation, the study said. The principles of functional architectures we studied here may also stimulate bio-inspired designs and fabrication of future composite materials for architectures of different scales, including wind turbines, artificial tissues, flying drones.

Chuong and Juan are co-leaders of the 31-person team, joined by co-authors Randall B. Widelitz, Shuo Wang, Michael Habib, Ting-Xin Jiang, Zhong-Lai Luo and Ping Wu of the Keck School of Medicine of USC; Wei-Ling Chang, Hao Wu, Yung-Chi Lai, Ming Xing Lei, and Shih-Chieh Hung of the China Medical University Hospital in Taiwan; Ming-You Shie, Jui-Ting Hsu, Heng-Li Huang and Yi-Wen Chen of the China Medical University, Taiwan; Chih-Feng Chen, Ping Chi Tang, Hus Chen Cheng, and Yen-Cheng Lin of the National Chung Hsing University in Taiwan; How-Jen Gu, Yu-Kun Chiu, Tse-Yu Lin, Shun-Min Yang, Tsung-Tse Lee, J.C. Tsai and Yeu-Kuang Hwu of the Institute of Physics, Academia Sinica, Taiwan; Cheng-Te Yao of the Endemic Species Research Institute, Taiwan; Shyh-Jou Shieh of the National Cheng Kung University, Taiwan; Ang Li of the University of Texas, Arlington.

Work at USC was supported by the National Institutes of Health (AR 047364, AR 060306) while team members in Taiwan were supported by grants from their own institutes and the Taiwan government.

More stories about: Biology, Research

View original post here:
How birds fly: New USC study examines the evolution of flight feathers - USC News

Skin Stem Cells Comments Off on How birds fly: New USC study examines the evolution of flight feathers – USC News | November 29th, 2019

Winter is not just for hot cocoa and cozy blankets; the season is not always kind to the skin.

When the air outside gets gold and dry, without proper care, you skin can quickly follow suit. Having dry skin is the most uncomfortable feeling in the world.

The entire winter season, dead skin cells can build up on the skin's surface, which would result in a dry and dull complexion. The cold weather can lead to chapped lips, cracked hands and dry flaky skin.

Once the temperatures drop, your skincare routine should rise to the challenge.

That's why it's important to moisturize at this time of the year. However, it's also important to keep exfoliation in your winter skincare routine, and here's why.

Exfoliation isn't something yo;ll need to put on the back burner. In fact, winter is one of the best times for exfoliations. If you aren't spending your snow days sloughing away dead skin, then you're totally missing out.

Exfoliations helps replenish the skin.

Between the dry indoor heating and the cold air outside, your skin cells need to hydrate. They easily die out faster in the colder season, so it's essential to buff away the dead cells so new cells can come in healthier. It's recommended to exfoliate at least twice a week.

Exfoliators improve the effectiveness of the moisturizers.

Because you'll be slapping extra heavy lotion for the winter, you'll want to maximize its power. Do this by exfoliating regularly. The dead cells block moisture from the layers of live skin cells that actually need it.

Exfoliating beads, salt or sugar scrubs, dry scrubbing or even common body sponges are best examples of physical exfoliants that will help tremendously.

The usual at-home scrubs are the sugar scrub and the salt scrub.

The difference between the two is that the sugar scrub is more gentle, less abrasive and tends to dissolve fast in warm water.

Whereas the salt scrub tends to be a little more aggressive because the granules are larger. With a salt scrub, you're going to want to exfoliate a little less than you would with a sugar scrub or other exfoliating beads.

Keep scrolling to check 5 of our top picks for adding some body scrub time to your tub or shower regime.

M3 Naturals Himalayan Salt Scrub

Detoxify the skin with the M3 Naturals Himalayan Salt Scrub. It is infused with collagen and stem cell that increases skin cell longevity. Combined, these deliver an anti-aging performance.

This salt scrub is made from an all-natural Himalayan pink salt with lychee fruit and almond oil that will provide moisture and cleans out impurities of the skin and will effectively remove dirt, oil and reduce the appearance of acne, scars, blackheads and cellulites.

(Photo : Amazon)

Dove Exfoliating Body Polish Body Scrub

This easy-to-find exfoliating body scub removes dull, dry skin while deeply nourishes it to restore its natural nutrients.

The product is formulated with moisturizing cream and has a whipped texture that provides a creamy coverage.

(Photo : Amazon)

Brooklyn Botany Arabica Coffee Scrub

A coffee body scrub that can be used on the face, hand and foot. It will easily remove dead skin giving you a fresher, younger and moisturized appearance.

It will also reduce the signs of aging because of the coffee's antoxidants, fighting the appearance of fine lines, sun spots and wrinkles.

(Photo : Amazon)

Majestic Pure Cosmeceuticals Sweet Orange Body Scrub

A vegan-friendly, bright and refreshing body scrub crafted with nourishing ingredeints such as sweet orange oil, dead sea salt, organic aloe vera juice and coconut oil.

Using this product can promote more supple and smooth skin, gently removing dead skin and exposing it to enriching and moisturizing minerals and nutrients.

(Photo : Amazon)

Shea Moisture Exfoliating Hand and Body Sugar Scrub

The sugar scrub is made from natural ingredeints that gently cleanses skin from impurities, pollutants and build-up. It is created with argan oil and organic raw shea butter.

It will provide your skin with intense moisture and can exfoliate your hand and body by removing dead skin cells.

(Photo : Amazon)

READ MORE: 7 Gifts that Will Not Break Your Bank Account this Christmas 2019

See Now: Famous Actors Who Turned Down Iconic Movie Roles

2019 ENSTARS, All rights reserved. Do not reproduce without permission.

Visit link:
5 Scrubs and Exfoliators You NEED This Winter 2019 - Enstarz

Skin Stem Cells Comments Off on 5 Scrubs and Exfoliators You NEED This Winter 2019 – Enstarz | November 29th, 2019

Mucopolysaccharidoses (MPS) are a group of very rare disorders, also known as orphan diseases. They belong to the group of lysosomal storage diseases which are caused by a deficiency of one of the enzymes involved in the degradation of mucopolysaccharides (the acid glycosaminoglycans or GAGs). The enzymes are coded by genes which produce deficient gene products due to gene variants in each of the two gene-alleles.

Children of two carriers as parents have a 25% risk to suffer from MPS. For many families, the birth of the first affected child is a shock and a disaster. The disease is continuously progressing, and life spans are dramatically decreased without therapy. As a result, extensive efforts are put into the cure of these fatal disorders.

Enzymes are relatively small proteins, produced in the endoplasmatic reticulum of each cell. Before reaching the locus of their function, the lysosomes, additional modifications with special sugars are performed in the Golgi apparatus (glycosylation). Via mannose-6-phosphate marker, they connect to the mannose-6-phosphat receptor on the lysosomal membrane and can reach the final locus of their function. In the lysosomes, enzymes degrade the GAG chains into the smallest molecules for recycling or excretion. Any disturbance in this process leads to the accumulation of non-degraded material, which affects many other cell functions such as homeostasis, calcium metabolism, accelerates apoptosis and induces inflammation processes.

As lysosomes are ubiquitous, any disturbance leads to storage in many different tissues and organs. MPSs are a good example for chronic progressive multi-systemic disorders. The best theoretical option for treatment of any patient is to supplement the missing enzyme which could reach any organ via blood flow and get inside the lysosomes continuing the interrupted degradation processes.

The enzymes are ubiquitous and have some tissue specific compositions. Enzymes produced in the different cells and tissues have their own characteristics and are available on site. The production of recombinant enzymes means that the artificial glycosylation is created in a uniform composition for intravenous substitution with the aim to reach the organs with the blood-flow. There is no doubt that the therapeutic efficacy is ideal for many organs, such as liver, spleen, lung, and skin. All these organs have a good blood circulation and some ability to regenerate.

However, after years of treatment with the already available enzymes, it is shown that some organs are poorly supplied with blood and renewal cycles are slow, the ability to regenerate is decreased. Organs such as bones, cartilage, muscles, cornea, heart valves, meninges or the brain do not show the hope-for effect. All MPS types with brain involvement (neuronopathic forms of MPS types I, II and VII) or predominant skeletal dysplasia (MPS types IVA and B) cannot benefit from enzyme-replacement therapy and do not show the desired improvement.

In animal studies, modifications of glycosylation can change the ability to pass into organs not yet sufficiently reached such as cartilage or bones, but tissue-specific features cannot be sufficiently considered in any artificial production of the enzymes.

Avascular cartilage, heart valves and corneas cannot be reached by blood flow. Also, between blood vessels and brain tissue, several specialised cells form the blood-brain-barrier (BBB) to protect the brain from any unwanted substances in the blood. Therefore, new strategies are necessary to improve the therapeutic efficiency and to provide better outcomes for the affected patients. If patients with MPS I are diagnosed at a very young age, the best option is to treat them with haematopoietic stem cell transplantation (HSCT). Migrating stem cells can reach the brain and other organs, and then differentiate into organ-specific cells producing the missing lysosomal enzymes.

A straightforward method to overcome BBB is the direct injection of a recombinant enzyme into the cerebral fluid. This can be by lumbar puncture (intra-thecal) or intra-ventricular injections in the brain ventricles. Effects can be observed, however unfortunately not all challenges can currently be solved. The liquor flow can be reduced by thickened meninges with storage and vertebral deformities, which are typical for the disease. However, the barrier between cerebral fluid and brain tissue has still not been fully studied. The half-life of enzymes is limited, and the procedure has to be repeated regularly. The clinical trials for patients with MPS I, II, IIIA and IIIB could show some reduced or reversed progression of CNS pathology but long-term effects remain unclear.

Another possibility to overcome BBB is to fuse the enzyme proteins with macromolecules which enter the brain through receptor mediated active transport systems. This physiological transport is known for hormones, neurotransmitters and many other proteins (such as transferrin and insulin). They are transported through the BBB directly into the brain via specific receptores, so, the strategy is to fuse the natural proteins with the artificial enzymes needed in the MPS patient. It is important to note that clinical trials could potentially still show some improvement in affected MPS patients.

Another method is to conjugate the therapeutic enzymes with nano-capsules and to then ferry them across BBB via transcytosis or other transport mechanisms directly into brain cells. Pharmacological chaperones have been proven to be effective in other lysosomal storage diseases such as Gaucher or Fabry disease. Chaperones are able to stabilise three-dimensional conformation of misfolded proteins, such as enzymes. This would be the case of genetic variants causing missense mutation and exchange of only one amino acid in the protein chain. The misfolding pathology reduces stability, half-life and effect of the genetically conditioned enzyme, whereas the chaperone can reverse this disadvantage and increase the activity and efficacy of the enzyme. As a result, pharmacological chaperones are a good option for some diseases and could therefore be an option for some MPS patients in the future.

Some genetic variants cause stop-codons and the production of truncated dysfunctional peptides without any enzymatic activity and degradation within the cell. Stop-codon read through therapy aims for the genetic correction on an RNA level, resulting in the production of a sufficiently functioning gene product. It is already used for some specific mutation for patients with Duchenne muscular dystrophy, but it is too early to predict positive results for patients with MPS I.

Another possibility in the future might be the use of GAG-reducing small molecules such as Genistein, Pentosam polysulfate or Rhodamine B. They are able to influence and/or reduce the synthesis of GAGs which cannot be degraded sufficiently by the genetically changed enzymes with reduced function.

To reduce the GAGs as substrate, could be a chance to create a better relation between substrate and the impaired substrate reducing enzyme. As a result, lysosomal storage could therefore be reduced. Substrate reduction therapy is an established therapeutic concept in some of the other lysosomal storage diseases, but the usefulness in MPS disorders still needs to be proven.

The genetic corrections of DNA sequences in patient cells are no longer only future options as they have now become a reality. Gene variants causing missing or impaired functioning gene products could be replaced by correct genetic sequences and genes. This can be made as an ex vivo approach, where stem cells or fibroblast are removed from the patient and are then cultured in vitro, genetically corrected and consecutively re-injected into the patient.

The genetically corrected DNA in the re-transplanted autologous cells is able to produce correct gene products (in terms of MPS, this is the specific enzyme). The amounts of newly produced enzymes might be sufficient to positively influence the disease course of the treated patients.

An in vivo approach utilises viral vectors which invade cells, and even cell nuclei. Such viruses used are adeno-associated-viruses or lenti-viruses. Such manipulated viruses with the corrective genetic material are directly injected into the patient where they are internalised into deficient cells and are then able to produce the missing gene product. In the case of MPS, the aim is to produce enzyme proteins with sufficient concentrations and activity to prevent the storage of GAGs. Furthermore, clinical trials are underway for several MPS types and therefore, might offer a therapeutic opportunity in early life for affected patients. However, larger studies and a longer follow-up is still needed.

To conclude, MPS are rare genetic disorders and for a long time, they were linked with the myth of being untreatable diseases. Although some of the new therapeutic options are still in clinical trials and not routinely used, the present shows that many of the patients can benefit from the yet available options of HSCT and enzyme replacement therapies. These therapies have an undoubted effect for some of the MPS patients, especially if any form of therapy is started early or if the course of the disease does not affect the nervous system.

However, in the future, new therapeutic options will hopefully bring benefits to those that are not sufficiently improved; the decision of the best therapy will be made on the basis of factors such as the genetic defect, the type of MPS, and the age during treatment. This individualised and personalised therapy will improve the success of MPSs therapies.

Susanne Gerit KircherMedical University of Vienna, AustriaCenter of Pathobiochemistry and Geneticssusanne.kircher@meduniwien.ac.atwww.mps-austria.at

Original post:
Mucopolysaccharidoses: future therapies and perspectives - SciTech Europa

Skin Stem Cells Comments Off on Mucopolysaccharidoses: future therapies and perspectives – SciTech Europa | November 29th, 2019

Although one in nine men will receive a prostate cancer diagnosis in his lifetime, cutting-edge research has allowed more men to live longer or even be cured.

One such program that sheds light on this cause is City of Hopes NoShaver November. The month-long fundraising and awareness campaign urges participants to forego shaving to start a conversation, encourage testing and raise critical funds to continue leading-edge prostate cancer research and promising new therapies conducted at City of Hope.

CURE recently spoke with Dr.Tanya Dorff, a medical oncologist at City of Hope who specializes in prostate cancer, about the campaign, her current work and where she sees the future of prostate cancer treatment shifting in the coming years.

CURE: What led you to City of Hope? What do you do there?Dorff: City of Hope was attractive to me because I am a clinical and translational researcher. The reason I came here was to work with scientists who share what we are seeing in the clinic and who incorporate the latest insights from the scientific discoveries in our laboratories into patient care. There is a real sense of mission and urgency that binds scientists to clinicians at City of Hope in a way that is unique and gratifyingly productive.First and foremost, I take care of patients who remain my central inspiration and raison detre, but I spend part of my time writing and running clinical trials that have real potential to impact how we treat patients in the future how we can do even better in the future than we do today. I lead the genitourinary cancer program, which includes fostering collaborations between the incredible physicians from urology, radiation oncology, radiology and pathology to work together both clinically and in research projects.You are Grammy-winning songwriter and vocal producer Kuk Harrells physician. Can you tell me what it was like to treat him?Kuk is such an incredible gentleman; it has been a pleasure to be part of his care team. His attitude toward treatment was one of diligence, and he has approached his illness as an opportunity for personal growth and for giving back by promoting prostate cancer awareness through his story. It has been inspiring to see him come through what was a lengthy and involved treatment with so much positive energy.How has the field of prostate cancer treatment evolved in recent years?More and more men with prostate cancer can be cured, and the men who cannot be cured with todays treatments are clearly living longer and better. This is thanks to new drug approvals in advanced, resistant prostate cancer but even more so to the application of more intensive therapy earlier in the course of the disease. This has been the biggest paradigm shift in prostate cancer over the last five years: up-front intensification in metastatic hormone sensitive prostate cancer.The next big shift in prostate cancer treatment is just now upon us molecular selection of therapies to individualize prostate cancer treatment. The most imminent example is olaparib (Lynparza), a PARP inhibitor, which worked better than standard treatment in patients with castration-resistant prostate cancer whose tumors harbor mutations in DNA repair genes. But the ingenious theranostic approach will be close behind where imaging (scans) show us whether a cancer is expressing a certain target (i.e. PSMA) and if so, a radioactive particle linked to that target is applied (i.e. Lu-177 PMSA).

What are you most hopeful for in cancer treatment in the future?I believe immunotherapy will be the way to durable remission or a cure. Here at City of Hope, we are working hard to improve the effectiveness of immunotherapy for patients with metastatic prostate cancer, studying intensive treatments such as CAR-T and bispecific T-cell engaging antibodies, among other approaches. Our scientists are looking at our patients in real time to learn why treatments work or dont work, and how to better engage the immune system. I am very hopeful that these biologic insights will eventually translate into therapeutic success such as we have seen in leukemia with CAR-T and melanoma with immune checkpoint inhibitors.What advice would you offer someone who has just received a cancer diagnosis of their own?One: Play an active role. Ask questions, and if something doesnt sound right or make sense, ask again. It is so important that patients buy into their treatment, understand and feel confident about the treatment plan. No one is perfect, not even the best doctor, and working together as a team will lead to the best success.

Two: Be a squeaky wheel. Patients who communicate symptoms in real time fare better because problems are addressed before they become more serious.

Three: Stay active. Exercise is one of the things that has been shown over and over again to help cancer survivors and cancer patients in various stages. Obviously, a conversation should occur with the treatment physicians to ensure that there are no restrictions but patients who are more active will come through treatment in better shape.

View original post here:
Exploring the Future of Prostate Cancer with City of Hope - Curetoday.com

Skin Stem Cells Comments Off on Exploring the Future of Prostate Cancer with City of Hope – Curetoday.com | November 29th, 2019

GammaDelta Therapeutics is a company that focusses on utilizing the unique properties of gamma delta () T cells to develop novel immunotherapies for patients.Through their research, the companys scientists have discovered a number of targets and antibodies that have the potential to modulate the activity of T-cells in situ. Therefore, GammaDelta Therapeutics recently announced the formation of Adaptate Biotherapeutics, a spin-out company that will focus on research in this area.

Technology Networks spoke with Natalie Mount, CEO of Adaptate BioTherapeutics, to learn more about the company's aims and the challenges faced when developing immunotherapies and advancing them into clinical studies.

Molly Campbell (MC) Please can you tell us more about T-cell based cell therapy products and their potential applications?Natalie Mount (NM): T cells play an increasingly appreciated critical role in immune surveillance, being able to recognize malignant/transformed cells through a pattern of stress markers. The recognition mechanism is not major histocompatibility complex (MHC) restricted and not dependent on a single antigen.

T cells therefore have potential in a range of disease indications, including both hematological and solid malignancies and a positive correlation between T cell infiltration and prognosis/survival in patients has been determined in a range of oncology indications in studies published in the literature by other groups. Additionally, as a cell therapy, T cells can be used in an allogeneic setting (ie, T cells can be used for unrelated recipients without a requirement for matching).

Both Adaptate Biotherapeutics and GammaDelta Therapeutics are focussed on harnessing the potential of T cells, in particular the V1 subtype which is the predominant T cell type in tissue.This is based on data originating from the labs of Professor Adrian Hayday of Kings College London and the Crick Institute, supported by Cancer Research Technology and also from Professor Bruno Silva Santos of Institute for Molecular Medicine at the University of Lisbon, Portugal.

Previous clinical trials conducted by other groups/companies targeting or using T cells in cancer have focussed on the V2 subtype which is predominant in the blood. These trials have demonstrated safety, but efficacy has been limited.Compared to V2 cells, V1 cells, which are the focus of work at Adaptate Biotherapeutics and GammaDelta Therapeutics, are less susceptible to exhaustion and activation induced cell death. Expansion of donor derived V1 has been shown to be a positive prognostic indicator for acute myeloid leukemia patients following hematopoietic stem cell transplant.

MC: Why are current immunotherapy treatment approaches limited?NM: Immunotherapy approaches have had very significant success and impact in Oncology recently, however, challenges and unmet needs remain.One challenge is effective treatment of solid tumors. The hypoxic, low nutrient tumor environment provides a challenge for successful infiltration and activation of T cells. However, V1 T cells have real potential as they are naturally tissue resident and hence primed for this environment. In addition, their ability to recognize malignant cells by a pattern of markers expressed by dysregulated, transformed cells rather than one specific antigen presented by the MHC provides an additional advantage for both specificity of response and maintenance of efficacy.

T cells act as orchestrators of an immune response and, following recognition of a cell as malignant, they induce maturation of monocytes and signal to alpha beta T cells, hence increasing immunogenicity of the tumor and providing a sustained response, with potential even in tumors with low mutational load which have proven challenging with other immunotherapies.

MC: The new spin-out company, Adaptate Biotherapeutics, will build on GammaDelta's knowledge to modulate T-cell activity using therapeutic antibodies. Why have you decided to create a spin-out focusing on this area of research?NM: GammaDelta Therapeutics was formed in 2016 to harness the unique properties of T cells, and since then has gained extensive knowledge of T-cell biology. In addition to gaining insight into cell growth and isolation, the companys scientists have also discovered a number of targets and antibodies that have potential to modulate the activity of T-cells in situ.

GammaDelta Therapeutics now has a pipeline of cell therapy products progressing into clinical development under the guidance of CEO, Dr Paolo Paoletti.

Adaptate Biotherapeutics will be developing antibodies which will be administered to cancer patients to modulate activity of the patient's gamma delta T cells in situ.

Delivery of cell therapy and antibody therapeutics each needs focus and specific skillsets and formation of two independent entities will facilitate this. The two companies share a common goal to harness the potential of T cells to bring effective therapies to patients. Both benefit from support of the scientific founding team and have common investors, Abingworth and Takeda Pharmaceuticals.MC; Your goal is to develop targets and antibodies that can modulate the activity of T-cells and advance them into clinical studies. What challenges exist here, and how do you hope to overcome them?

Our assets at Adaptate Biotherapeutics are currently at the pre-clinical stage and therefore face the non-clinical development risks for a novel therapy. However, these risks are mitigated by biology understanding from our scientific founders and the work at GammaDelta Therapeutics to date.

One of our challenges is in selecting the most suitable patient population for initial trials. There is potential for opportunity for our therapeutics in multiple indications but the utility of animal models in modelling the human immune compartment and human tumor setting is limited. Therefore in vitro and ex vivo models are important, in addition to the learnings from other clinical studies.

MC: GammaDelta Therapeutics formed in 2016 to gain extensive knowledge of T-cell biology and to developing a portfolio of investigational cell therapies. Some of these cell therapies are poised to enter clinical development. Can you tell us any further information about these therapies?NM: GammaDelta was set up to develop cell-based therapy utilizing ex-vivo expanded tissue resident gd T cells. Subsequent acquisition of Lymphact SAS allowed GammaDelta to augment its capabilities with a platform for ex-vivo expansion of blood derived V1 cells. GammaDelta is focussed on progressing ex-vivo expanded skin and blood derived V1 cells to the clinic both in unengineered and engineered formats. Clinical trials are currently on track to commence in the next 12-18 months.

MC: Your press release states: "The two companies will continue sharing their insights into T-cell biology as they work towards developing different therapeutic modalities". How will you continue to share insights here?NM: Antibodies and cells represent complementary approaches to realizing the potential of T cell activity for patients with solid and haematological malignancies.

The two companies will work together in areas of common interest in the biology of these fascinating cells, such as understanding the phenotype and behavior of T cells in tumors and mechanisms of cell regulation as well as the effects of antibody on the T cells.

We have deliberately established a contractual framework that allows efficient collaboration between scientists of both the companies via formal and informal meetings.

MC: What are your hopes for the future of Adaptate Biotherapeutics?NM: This is a remarkable time in the development of new immune therapies, and the role of "non-conventional" cell types of the immune system is coming to the fore as we recognize the successes achieved to date and the needs of patients and related scientific challenges that remain.

Both GammaDelta Therapeutics and Adaptate Biotherapeutics are at the lead of translating our increasing understanding of T cell biology and its potential into therapies to address these unmet needs.

Adaptate Biotherapeutics has a fantastic opportunity to build and accelerate a portfolio of antibody-based approaches in this novel area and I look forward to the successful translation of this science into therapies with the support of our investors at Abingworth and Takeda Pharmaceuticals.

Dr Natalie Mount, CEO of Adaptate Biotherapeutics was speaking with Molly Campbell, Science Writer, Technology Networks.

Continue reading here:
Harnessing Gamma T Cells To Bring Effective Therapies to Patients - Technology Networks

Skin Stem Cells Comments Off on Harnessing Gamma T Cells To Bring Effective Therapies to Patients – Technology Networks | November 28th, 2019

DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Genome Editing Services Market-Focus on CRISPR 2019-2030" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographical regions.

Currently, there is an evident increase in demand for complex biological therapies (including regenerative medicine products), which has created an urgent need for robust genome editing techniques. The biopharmaceutical pipeline includes close to 500 gene therapies, several of which are being developed based on the CRISPR technology.

Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. However, successful gene manipulation efforts involve complex experimental protocols and advanced molecular biology centered infrastructure. Therefore, many biopharmaceutical researchers and developers have demonstrated a preference to outsource such operations to capable contract service providers.

Consequently, the genome editing contract services market was established and has grown to become an indispensable segment of the modern healthcare industry, offering a range of services, such as gRNA design and construction, cell line development (involving gene knockout, gene knockin, tagging and others) and transgenic animal model generation (such as knockout mice). Additionally, there are several players focused on developing advanced technology platforms that are intended to improve/augment existing gene editing tools, especially the CRISPR-based genome editing processes.

Given the rising interest in personalized medicine, a number of strategic investors are presently willing to back genetic engineering focused initiatives. Prevalent trends indicate that the market for CRISPR-based genome editing services is likely to grow at a significant pace in the foreseen future.

Report Scope

One of the key objectives of the report was to evaluate the current opportunity and the future potential of CRISPR-based genome editing services market. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030.

In addition, we have segmented the future opportunity across [A] type of services offered (gRNA construction, cell line engineering and animal model generation), [B] type of cell line used (mammalian, microbial, insect and others) and [C] different geographical regions (North America, Europe, Asia Pacific and rest of the world).

To account for the uncertainties associated with the CRISPR-based genome editing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION3.1. Context and Background3.2. Overview of Genome Editing3.3. History of Genome Editing3.4. Applications of Genome Editing3.5. Genome Editing Techniques3.5.1. Mutagenesis3.5.2 Conventional Homologous Recombination3.5.3 Single Stranded Oligo DNA Nucleotides Homologous Recombination3.5.4. Homing Endonuclease Systems (Adeno Associated Virus System)3.5.5. Protein-based Nuclease Systems3.5.5.1. Meganucleases3.5.5.2. Zinc Finger Nucleases3.5.5.3. Transcription Activator-like Effector Nucleases3.5.6. DNA Guided Systems3.5.6.1. Peptide Nucleic Acids3.5.6.2. Triplex Forming Oligonucleotides3.5.6.3. Structure Guided Endonucleases3.5.7. RNA Guided Systems3.5.7.1. CRISPR-Cas93.5.7.2. Targetrons3.6. CRISPR-based Genome Editing3.6.1. Role of CRISPR-Cas in Adaptive Immunity in Bacteria3.6.2. Key CRISPR-Cas Systems3.6.3. Components of CRISPR-Cas System3.6.4. Protocol for CRISPR-based Genome Editing3.7. Applications of CRISPR3.7.1. Development of Therapeutic Interventions3.7.2. Augmentation of Artificial Fertilization Techniques3.7.3. Development of Genetically Modified Organisms3.7.4. Production of Biofuels3.7.5. Other Bioengineering Applications3.8. Key Challenges and Future Perspectives

4. CRISPR-BASED GENOME EDITING SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE4.1. Chapter Overview4.2. CRISPR-based Genome Editing Service Providers: Overall Market Landscape4.2.3. Analysis by Type of Service Offering4.2.4. Analysis by Type of gRNA Format4.2.5. Analysis by Type of Endonuclease4.2.6. Analysis by Type of Cas9 Format4.2.7. Analysis by Type of Cell Line Engineering Offering4.2.8. Analysis by Type of Animal Model Generation Offering4.2.9. Analysis by Availability of CRISPR Libraries4.2.10. Analysis by Year of Establishment4.2.11. Analysis by Company Size4.2.12. Analysis by Geographical Location4.2.13. Logo Landscape: Distribution by Company Size and Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS5.1. Chapter Overview5.2. Methodology5.3. Assumptions and Key Parameters5.4. CRISPR-based Genome Editing Service Providers: Competitive Landscape5.4.1. Small-sized Companies5.4.2. Mid-sized Companies5.4.3. Large Companies

6. COMPANY PROFILES6.1. Chapter Overview6.2. Applied StemCell6.2.1. Company Overview6.2.2. Service Portfolio6.2.3. Recent Developments and Future Outlook6.3. BioCat6.4. Biotools6.5. Charles River Laboratories6.6. Cobo Scientific6.7. Creative Biogene6.8. Cyagen Biosciences6.9. GeneCopoeia6.10. Horizon Discovery6.11. NemaMetrix6.12. Synbio Technologies6.13. Thermo Fisher Scientific

7. PATENT ANALYSIS7.1. Chapter Overview7.2. Scope and Methodology7.3. CRISPR-based Genome Editing: Patent Analysis7.3.1. Analysis by Application Year and Publication Year7.3.2. Analysis by Geography7.3.3. Analysis by CPC Symbols7.3.4. Emerging Focus Areas7.3.5. Leading Players: Analysis by Number of Patents7.4. CRISPR-based Genome Editing: Patent Benchmarking Analysis7.4.1. Analysis by Patent Characteristics7.5. Patent Valuation Analysis

8. ACADEMIC GRANT ANALYSIS8.1. Chapter Overview8.2. Scope and Methodology8.3. Grants Awarded by the National Institutes of Health for CRISPR-based8.3.1. Year-wise Trend of Grant Award8.3.2. Analysis by Amount Awarded8.3.3. Analysis by Administering Institutes8.3.4. Analysis by Support Period8.3.5. Analysis by Funding Mechanism8.3.6. Analysis by Type of Grant Application8.3.7. Analysis by Grant Activity8.3.8. Analysis by Recipient Organization8.3.9. Regional Distribution of Grant Recipient Organization8.3.10. Prominent Project Leaders: Analysis by Number of Grants8.3.11. Emerging Focus Areas8.3.12. Grant Attractiveness Analysis

9. CASE STUDY: ADVANCED CRISPR-BASED TECHNOLOGIES/SYSTEMS AND TOOLS9.1. Chapter Overview9.2. CRISPR-based Technology Providers9.2.1. Analysis by Year of Establishment and Company Size9.2.2. Analysis by Geographical Location and Company Expertise9.2.3. Analysis by Focus Area9.2.4. Key Technology Providers: Company Snapshots9.2.4.1. APSIS Therapeutics9.2.4.2. Beam Therapeutics9.2.4.3. CRISPR Therapeutics9.2.4.4. Editas Medicine9.2.4.5. Intellia Therapeutics9.2.4.6. Jenthera Therapeutics9.2.4.7. KSQ Therapeutics9.2.4.8. Locus Biosciences9.2.4.9. Refuge Biotechnologies9.2.4.10. Repare Therapeutics9.2.4.11. SNIPR BIOME9.2.5. Key Technology Providers: Summary of Venture Capital Investments9.3. List of CRISPR Kit Providers9.4. List of CRISPR Design Tool Providers

10. POTENTIAL STRATEGIC PARTNERS10.1. Chapter Overview10.2. Scope and Methodology10.3. Potential Strategic Partners for Genome Editing Service Providers10.3.1. Key Industry Partners10.3.1.1. Most Likely Partners10.3.1.2. Likely Partners10.3.1.3. Less Likely Partners10.3.2. Key Non-Industry/Academic Partners10.3.2.1. Most Likely Partners10.3.2.2. Likely Partners10.3.2.3. Less Likely Partners

11. MARKET FORECAST11.1. Chapter Overview11.2. Forecast Methodology and Key Assumptions11.3. Overall CRISPR-based Genome Editing Services Market, 2019-203011.4. CRISPR-based Genome Editing Services Market: Distribution by Regions, 2019-203011.4.1. CRISPR-based Genome Editing Services Market in North America, 2019-203011.4.2. CRISPR-based Genome Editing Services Market in Europe, 2019-203011.4.3. CRISPR-based Genome Editing Services Market in Asia Pacific, 2019-203011.4.4. CRISPR-based Genome Editing Services Market in Rest of the World, 2019-203011.5. CRISPR-based Genome Editing Services Market: Distribution by Type of Services, 2019-203011.5.1. CRISPR-based Genome Editing Services Market for gRNA Construction, 2019-203011.5.2. CRISPR-based Genome Editing Services Market for Cell Line Engineering, 2019-203011.5.3. CRISPR-based Genome Editing Services Market for Animal Model Generation, 2019-203011.6. CRISPR-based Genome Editing Services Market: Distribution by Type of Cell Line, 2019-203011.6.1. CRISPR-based Genome Editing Services Market for Mammalian Cell Lines, 2019-203011.6.2. CRISPR-based Genome Editing Services Market for Microbial Cell Lines, 2019-203011.6.3. CRISPR-based Genome Editing Services Market for Other Cell Lines, 2019-2030

12. SWOT ANALYSIS12.1. Chapter Overview12.2. SWOT Analysis12.2.1. Strengths12.2.2. Weaknesses12.2.3. Opportunities12.2.4. Threats12.2.5. Concluding Remarks

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/78rwbq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/genome-editing-services-world-markets-to-2030-focus-on-crispr---the-most-popular-genome-manipulation-technology-tool-300966100.html

SOURCE Research and Markets

See more here:
Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - P&T Community

Skin Stem Cells Comments Off on Genome Editing Services, World Markets to 2030: Focus on CRISPR – The Most Popular Genome Manipulation Technology Tool – P&T Community | November 28th, 2019

.

The Black Friday sales are almost among us, meaning the halls of your local department store are about to become a battleground. (The smartest of shoppers know the key to maintaining sanity is to do it all online.)

But when faced with deals and discounts from every angle, its crucial to keep your cool. You dont want to panic-buy all those as-seen-on-Instagram products before youre covered the essentials you know, the things you'll use day in, day out, until they're empty.

Resist those shiny, sparkling impulse buys (although yes, that glitter lipstick would look pretty good on NYE), and youll come out triumphant with a well-curated skincare edit that will keep your skin happy long after the last Quality Street has been polished off.

So, skip the scrolling and head straight for the good stuff this year. Here, discover the eight most unequivocally iconic beauty products we've spotted in the Black Friday sales. Trust us: you cannot go wrong with any (or all) of these heroes.

Advertisement - Continue Reading Below

1Soleil Tan De Chanel

Chanel

WAS 40 NOW 36

Soleil Tan de Chanel is the kind of product beauty dreams are made of. The weighty pot will last you all year, while the lacquered, double-C engraved pot will look incredibly bouji on your dressing table.

But of course,it's what's on the inside that really counts, and boy is this a brilliantly formulated bronzer. Unlike literally anything else on the market (many brands have tried and failed to 'dupe' it), this dense, mattecream can be picked up with a powder brush, dusted under or over foundation, and swiped strategically to carve out killer cheekbones it's revolutionary.

2Blanche Eau de Parfum

Byredo

WAS 110 NOW 93.50

Byredo's perfumes are coveted the world over, but with so many to choose from, you'll be hard-pressed to find a favourite without some kind of divine intervention.

Our advice? Head straight for Blanche, which is a byword for the crispest, cleanest scent you'll ever spritz. Forget cloying talc notes or blink-and-you'll-miss-it citrus: this is pure violet and musk-tinted freshness, like the cleanest cotton sheets that ever were.

And seeing as there's a very generous 15% discount (thank you, Liberty), maybe treat yourself to the body wash, too.

3The Rich Cream

205.00

WAS 205 NOW 174

The hype around Augustinus Bader's debut product was remarkable across the world, A-listers and beauty editors fawned. (Victoria Beckham even tapped him up to create her debut skincare product.)

Turns out, this clever cream really delivers. The secret is the Trigger Factor Complex, which works to kick-start the natural healing process of the body's stem cells. 30 years of research and development have clearly paid off.

4Bronzing Powder

Narsasos.com

WAS 31 NOW 24.50

The name of many a Nars product precedes its performance Orgasm, anyone? But not this one: the brand's Laguna and Casino bronzing powdersare famed for their supreme performance alone.

Both illuminate without relying on glitter (which always looks fake), and are warming without imparting those giveaway ruddy undertones.

Paler skins are destined for Laguna, while darker tones will love Casino. Your bank balance will love either.

5Diorshow Pump 'N' Volume HD Mascara

DIOR

WAS 28 NOW 25.20

Ask any beauty editor what their ride-or-die mascara is and you'll get...a lot of conflicting opinions.

Like the perfect shade of red lipstick, a favourite mascara is a subjective thing. After all,few can deliver perfection when it comes to length, volumeand colour. Enter Dior's Pump 'N' Volume: the mascara to unite us all. (And yes, it's the one with the no-wastesqueezy tube.)

6Do Son Eau De Parfum

Diptyque

WAS 120 NOW 96

Many of Diptyque's fragrances could be considered iconic, but Do Son is the one that'll see you being stopped by strangersin the street.

The tuberose trail is enticing enough, but it's the unusual addition of orange blossom and jasmine that take things to truly memorable heights. A spectacularode to its namesake beach, in Vietnam's Ha Long Bay.

7Ruby Woo Matte Lipstick

WAS 17.50 NOW 14

If you're a 'lipstick person', you already know about this one. You've likely got one stashed in your bag right now, as well as one on your dresser, and an 'emergency' onefloating around your bedroom somewhere.

So good it's never been successfully imitated, MAC's Ruby Woo is the ultimate lipstick. A true red, it's neither too orange or too blue, and there's no skin tone it won't look beautiful against.

8Glow Tonic

WAS 18 NOW 15.30

We all know that alpha-hydroxy-acids are the gold standard when it comes to resurfacing, but so many require a degree in dermatology to use correctly.

Forgo the faffing in favour of Pixis cult Glow Tonic: it might look cute, but its packed with 5% brightening glycolic acid alongside soothing aloe vera. Simply sweep it over cleansed skin nightly no brow-furrowing required.

Advertisement - Continue Reading Below

Read more:
The 8 Most Iconic Beauty Products In The Black Friday Sales To Buy Now - elle.com

Skin Stem Cells Comments Off on The 8 Most Iconic Beauty Products In The Black Friday Sales To Buy Now – elle.com | November 28th, 2019

Soon youll be able to cover your imperfect flesh with more flesh.

Japanese cosmetics company Kao Corporation has developed a custom synthetic spray-on skin to cover unwanted blemishes, moles or other marks on the natural epidermis.

The artificial product, called est, is composed of tiny, liquid fibers. When sprayed, the substance adheres to human skin, transforming into an extremely thin, derma-like material, the Daily Mail reports.

It has a similar elasticity to skin, and its porous, too. Water vapor and air can pass through this second skin to moisten the living dermis beneath. At its edges, est forms an even thinner bond, helping it blend in with natural flesh.

Est is set to hit the market exclusively in Japan beginning Dec 4. and will sell for roughly $532 as a diffuser and potion combination, with diffuser refills priced at $73. A lotion version will sell for $110, and everything will become available online in January, according to Japanese publication the Asahi Shimbun.

Japanese-language advertisements for the product call it Future Skin, which uses Fine Fiber Technology. Kao has plans to expand the line beginning next year and hopes to soon enter the medical market.

Until then, American consumers can check out the SkinGun by RenovaCare, which shoots a liquid mist infused with human stem cells and can help burn victims skin.

Kao Japan

Kao Japan

Kao Japan

Kao Japan

Kao Japan

Read the original here:
Makeup brand offers spray-on 'skin' to cover up zits and scars - New York Post

Skin Stem Cells Comments Off on Makeup brand offers spray-on ‘skin’ to cover up zits and scars – New York Post | November 27th, 2019

27 Nov 2019

Twenty years ago, researchers took fibroblasts from the skin of eight Alzheimers patients, engineered them to produce nerve-growth factor, and slid them into each volunteers basal forebrain. They hoped the neurotrophin would halt or slow the neurodegeneration that robbed them of their memories, indeed their lives. The gamble failed and since then, scientists have shown little zest for gene therapy in neurodegenerative disorders. That is changing. As evident at this years Society for Neuroscience conference, held October 1923 in Chicago, gene therapy is back. Buoyed by success in treating spinal muscular atrophy in infants, scientists are flush with new ideasand funding.

What was once considered risky, expensive, and unlikely to succeed is now seen by many as risky, expensiveand quite likely to succeed. A growing number of scientists think gene-based therapies may have the best chance of slowing, or even preventing, neurodegeneration, especially for disorders caused by mutations in a single gene. SfN hosted a press briefing on gene therapy, plus many projects are active throughout the field beyond those showcased at the conference. There was no breaking clinical trial news at the annual meeting, but the scope and challenges of such therapies were outlined at the briefing moderated by Rush University s Jeff Kordower, Chicago, as well as a translational roundtable moderated by Asa Abeliovich, Columbia University, New York. Abeliovich recently co-founded Prevail Therapeutics, New York.

Going viral. Researchers are tweaking the capsid of adeno-associated viruses to optimize gene therapies for a multitude of disease. Shown here, AAV2.

From Zolgensma to Alzheimers? If the failure of the nerve growth factor therapy tempered enthusiasm for gene therapy (Mar 2018 news), then the success of AVXS-101, aka Zolgensma, reignited it. Developed by scientists at Nationwide Childrens Hospital, Columbus, Ohio, and AveXis, Bannockburn, Illinois, AVXS-101 uses an adeno-associated virus to deliver billions of copies of the survival motor neuron 1 gene to the brain. A small pilot trial tested the therapy in babies with spinal muscular atrophy (SMA) Type 1, the severest form of this neurodevelopmental disease. Lacking functional SMN1, these infants face progressive muscle weakness. Most die before their second birthday; those who live need a ventilator to breathe.

In Phase 1, AVXS-101 dramatically improved motor function of 15 treated infants; all were living 20 months later when historical data predicted only one would survive. Twelve babies who received the highest dose grew stronger within months, most sitting independently and rolling over. They hit the highest score on a scale of motor function, whereas untreated babies deteriorated. By 20 months, two of the treated babies had begun to walk (Mendell et al., 2017). The Food and Drug Administration approved zolgensma in May 2019. At SfN in Chicago, Petra Kaufmann, AveXis, played videos of the first patients treated with AVXS-101. Some four years later, they are walking, running, and appear to be playing almost normally. A video of a little girl walking downstairs with nary a hint of having SMA Type I visibly moved the audience.

Scientists say its a game-changer. It is really the tremendous success with SMA that has renewed interest in gene therapy, said Clive Svendsen, Cedars-Sinai Regenerative Medicine Institute, Los Angeles. Speaking with Alzforum before SfN, Bart De Strooper, Dementia Research Institute, London, said the same. The success in SMA patients of both gene therapy and antisense therapy has revived interest in the whole area, De Strooper said. Nowadays, researchers tend to lump gene therapy and antisense therapy under one moniker, i.e., gene-based therapy. The SMA antisense therapy nusinersen also works in babies with SMA Type 1 and is FDA-approved (Nov 2016 news; May 2018 conference news). Unlike gene therapy, antisense therapy needs to be delivered indefinitely.

How About Neurodegenerative Disease?At SfN, scientists outlined strategies for treating adults who face years of decline due to Alzheimers, amyotrophic lateral sclerosis, frontotemporal dementia, Huntingtons (HD) and Parkinsons diseases (PD), or other synucleinopathies. Some are being tested in clinical trials, others are in preclinical development. Some target specific losses or gains of function, others aim to rescue dying neurons more broadly. Scientists also believe that working on rare childhood diseases of lysosomal storage may give them an opening to treat this common phenotype in age-related neurodegeneration, as well.

Just this October, an ApoE gene therapy trial started enrolling. Led by Ronald Crystal at Weill Cornell Medical College, New York, it will inject adeno-associated virus carrying the gene for ApoE2 into patients with early to late-stage AD who inherited two copies of ApoE4. The idea is to flood their brains with the protective allele of this apolipoprotein to try to counteract the effects of the risk allele. AAV-rh10-APOE2 will be injected directly into the subarachnoid cisternae of participants brains. The Phase 1 trialwill recruit 15 patients with biomarker-confirmed AD. Beverly Davidson, Childrens Hospital of Philadelphia, has a similar ApoE2 gene therapy in preclinical development.

At SfN, Abeliovich detailed Prevails programs for forms of PD and for frontotemporal dementias that are caused by risk alleles. A trial has begun for a glucocerebrosidase-based gene therapy. The enzyme GCase is essential for lysosomes to function properly. People who have loss-of-function mutations in both copies of the GBA1 gene develop Gauchers, a lysosomal storage disease. The severest form starts in babies, most of whom die before age 2. Milder forms cause later-onset Gauchers, while heterozygous mutations in GBA1 increase risk for Parkinsons, making restoration of GCase an obvious strategy for PD. Some researchers are trying to develop ways to boost activity of the mutated enzyme (e.g., Oct 2019 news), whereas Abeliovich and colleagues have constructed AAV-9 vectors to deliver normal GBA1 into the brain to restore GCase production.

In preclinical studies, the AAV9-GBA1 construct PR001 rescued both lysosomal and brain function in models of GCase deficiency and of Parkinsons, Abeliovich said. In mice fed the GCase inhibitor conduritol epoxide (CBE), PR001 injected into the brain ventricles beefed up GCase activity and reduced glycolipid accumulation, which is a sign that lysosomes are functional. A single dose worked for at least six months. Similar results were seen in a commonly used model of Gauchers that expresses the V394L GBA mutation and only weakly expresses prosaposin and saposins, lysosomal proteins that metabolize lipids. In these 4L/PS-NA mice, PR001 made increased levels of active GCase, fewer lipids accumulated, and the mice were more mobile on a balance beam. 4L/PS-NA mice also accumulate -synuclein, the major component of Lewy bodies in PD and other synucleinopathies. In these mice, and also in A53T -synuclein mice made worse with CBE, PR001 halved the amount of insoluble -synuclein, Abeliovich reported at SfN.

In search of the right dose for humans, the scientists next turned to nonhuman primates. They injected PR001 into the cisterna magna in hopes AAV9 would broadly distribute throughout the brain. At the highest dose, 8 x 1010 capsids per gram of brain weight, exposure in the brain was similar to that seen in the mice. The virus permeated the spinal cord, frontal cortex, hippocampus, midbrain, and putamen.

Also in October, Prevail scientists began recruiting for a Phase 1/2 double-blind, sham-controlled trial to test this gene therapy in 16 people with moderate to severe PD, who have mutations in one or both copies of their GBA1 genes. Six patients each will receive a low or high dose of PR001A. Blood and CSF biomarkers to be analyzed at three and 12 months, and at follow-up, include GCase, lipids, -synuclein, and neurofilament light chain. Participants will also undergo cognitive, executive, and motor-function tests and brain imaging. A Phase 1/2 trial of PR001 in neuronopathic Gauchers, which affects the brain and spinal cord, will start soon, Abeliovich said.

Other groups are boosting dopamine production in Parkinsons by way of gene therapy. VY-AADC,developed by Voyager Therapeutics, Cambridge, Massachusetts, packages the gene for L-amino acid decarboxylase (AADC), which converts L-dopa into dopamine, in an AAV-2 vector that is delivered into the brain. Two Phase 1 open-label trials are testing safety and efficacy. Both the PD-1101 and PD-1102 trials use MRI to guide injections of the vector bilaterally into the putamina of 15 or 16 patients, respectively. According to preliminary results presented at the annual meeting of the American Academy of Neurology this past May, the virus penetrated half of the putamen and AADC activity, as judged by 18F-DOPA PET, increased by 85 percent in the latter study. Seven of eight treated patients reported improvement after a year, along with longer on time on L-DOPA, and shorter off time. Off time is the period when L-DOPA effects wear off and patients experience loss of motor control. RESTORE-1, a Phase 2 study of 42 patients, started in 2018 and will run to the end of 2020.

Long-Lived Gene Therapy. When a Parkinsons disease patient died eight years after neurturin gene therapy, the trophin was still being expressed in their putamen (top left) and substantia nigra (bottom left), where it corresponded with tyrosine hydroxylase activity (right). [Courtesy of Jeff Kordower.]

Also in PD, Kordower and colleagues plan to re-evaluate neurturin-based gene therapy. Previously, the gene for this neurotrophin was delivered in an AAV2 vector into the brains of Parkinson patients in Phase 1 and 2 trials. This did not improve motor function. Even so, in Chicago Kordower showed that in two patients who died eight and 10 years later, the inserted gene was still expressing neurturin and that dopamine levels were higher on the injected than the contralateral side of the substantia nigra/putamen. This shows us that long-term gene expression can be achieved in the human brain, said Kordower (see image above). He believes that by focusing delivery with ultrasound, or tweaking the capsid itself, he may be able to generate enough gene expression to improve function.

Separately, AAV-GAD, a gene therapy for PD that showed promise in Phase 2 (Mar 2011 news) was acquired by MeiraGTx, New York, which will continue to develop it in the U.S. and Europe, according to founder Samuel Waksal (Nov 2018 news).

For its part, Prevail has a gene transfer construct for frontotemporal dementia in the pipeline, as well. Called PR006, it carries GRN, the gene encoding progranulin, on an AAV9 vector. GRN mutations cause familial FTD and, much like GBA mutations, do their dirty work via lysosomal dysfunction. In Chicago, Abeliovich reported that PR006 boosted progranulin release from neurons derived from FTD-GRN patients, nearly doubling their levels of mature Cathepsin D, the lysosomal protease that chops progranulin into granulins and indicates healthy lysosomes. In progranulin knockout mice, PR006 restored brain GRN expression and progranulin secretion into the CSF. Abeliovich said he expects a Phase 1/2 clinical trial in FTD patients to start in early 2020.

The biotech company Passage Bio, Philadelphia, is planning for clinical trials early next year with its AAV-GRN vector. MeiraGTx, New York, is banking on a different approach for FTD. They have developed an AAV carrying UPF1, which encodes regulator of nonsense transcripts 1. This protein helps clear out aberrant RNAs through a process call nonsense-mediated decay. MeiraGTx hopes this will restore homeostasis to RNA processing. AAV-UPF1 will be trialed for FTD and all forms of ALS bar those caused by mutations in SOD1. For SOD ALS, Novartis, Basel, Switzerland, and REGENXBIO, Rockville, Maryland, have a vector in preclinical testing.

For his part, Svendsen is taking a different approach. His lab tackles ALS with ex vivo gene therapy. The idea is to engineer clinical-grade human stem cells to produce glial-derived growth factor, and inject them into the spinal cord, much like the early NGF studies did in AD. Svendsen hopes the cells will churn out enough of the neurotrophin to protect spinal cord motor neurons. In a Phase 1/2a trial, 18 ALS patients have received these cells into one side of their spinal cords, such that each person serves as his or her own control. If this works, they would regain mobility only on the injected side. The trial finished in October; Svendsen expects results to come out in a few months. In a follow-up study, the scientists are trying to do the same with induced pluripotent stem cells. This would allow them to transplant autologous cells into patients, avoiding immune rejection

Other groups are deploying gene therapy as a way to improve immunotherapy, shield neurons from stress, or even generate neurons from astrocytes to make up for those lost to neurodegeneration.Tom Fagan

Go here to read the rest:
Time to Try Again: Gene-Based Therapy for Neurodegeneration - Alzforum

Skin Stem Cells Comments Off on Time to Try Again: Gene-Based Therapy for Neurodegeneration – Alzforum | November 27th, 2019

The warnings are already up in the popular press: Conversations during the Thanksgiving feast can be hazardous if they veer into political territory. But political talk can take place in theory: A data research company has now determined what topics are safe to talk about on the holiday.

With some qualitative analysis and a little common sense, weve created a cheat sheet that will help you blaze a path through Thanksgiving dinner that steers clear of treacherous political pitfalls and dangerous inter-uncle conflicts, reports Ranker.com, a Los Angeles-based media company which uses crowdsourcing to rank public opinion on multiple topics, typically at the rate of 15 million votes a month.

They have determined what political topics are the least and the most likely to set off a Thanksgiving dinner squabble. Their judgment is based on 300,000 votes from 40,000 respondents.

The topics to avoid this year: Abortion, immigration, terrorism and gender equality. The topics which are safe for dinnertime discussion: Ineffective government, health care reform and education.

If there are millennials present, they will be triggered, the organization says, by talk of abortion, police brutality and pollution. Generation X members will be set off by such topics as homelessness, affordable housing and campaign finance reform. Baby boomers will go to battle over terrorism, immigration and the moral decline of the nation.

The organization also has warnings for dinner hosts in certain states. If they live in Florida, their guests will be particularly sensitive about discussions of vaccines. In Indiana, its gender equality while Georgia diners are prone to fight over police brutality. Beware of talking about gun control at dinner tables in both California and Missouri; Texans get feisty over moral decline. New Yorkers get upset over transgender issues.

We examined each issue on a case-by-case basis to find the topics that are most likely to cause disagreement, as well as the ones on which people tend to either agree or not care about, Ranker.com explains.

A VERY SPECIALIZED MEAL

While most of us are enjoying turkey and pumpkin pie on Thanksgiving, the staff at one laboratory at Cedars-Sinai Medical Center in Los Angeles will be busy serving a meal to stem cells.

Stem cells do not observe national holidays, says Loren Ornelas-Menendez, manager of the very specialized lab that converts samples of adult skin and blood cells into stem cells which the human body uses to make our cells in the first place.

These special cells help medical scientists learn how diseases develop and how they might be cured. The lab is tending millions of them. Oh, but they have needs.

Stem cells are living creatures that must be hand-fed a special formula each day, monitored for defects and maintained at just the right temperature. And that means the cell lab is staffed every day, 52 weeks a year, the lab notes in a public advisory.

Many people have dogs. We have stem cells, says Ms. Ornelas-Menendez.

Derived from hundreds of healthy donors and patients, the resident induced pluripotent stem cells or iSPCs are keys to potential treatments for diabetes, breast cancer, Alzheimers disease, blindness, Parkinsons disease and Crohns disease, among other conditions. Ten lab technicians monitor the cells through microscopes each day and cull out any cells which have gone awry for one reason or another.

But what do they eat even on Thanksgiving?

While the cells get sorted, a special feeding formula is defrosting in a dozen bottles spread around a lab bench. The formula includes sodium, glucose, vitamins and proteins. Using pipettes, employees squeeze the liquid into food wells inside little compartments that contain the iPSCs. Afterward, they return the cells to their incubators, the lab advises.

Lab director Dhruv Sareen suggests that people consider offering a toast to the stem cells on Thanksgiving.

One day the cells they tend could lead to treatments for diseases that have plagued humankind for centuries, he says. And thats something to be truly thankful for.

THE GIPPERS FAVORITE

Back by popular demand, Inside the Beltway again shares this little known but historic recipe for President Reagans Favorite Macaroni and Cheese enjoyed by Ronald Reagan and his family on Thanksgiving and other holidays. What follows is a step-by-step shared by Mrs. Ronald Reagan, Washington, D.C., Wife of the President in a spiral-bound community cookbook published by the American Cancer Societys Northern Virginia division in 1983. The recipe serves six and is baked at 350 degrees F for 45 minutes.

The directions are from the cookbook reflecting the style, perhaps, of another era:

1/2 pound macaroni, 1 teaspoon butter, 1 egg, beaten; 1 teaspoon salt, 1 teaspoon dry mustard, 3 cups grated cheese, sharp; 1 cup milk.

Boil macaroni in water until tender and drain thoroughly. Stir in butter and egg. Mix mustard and salt with 1 tablespoon hot water and add to milk. Add cheese leaving enough to sprinkle on top. Pour into buttered casserole, add milk, sprinkle with cheese. Bake until custard is set and top is crusty.

Curious about what transpired at a Reagan Thanksgiving? A 1985 Los Angeles Times account noted this:

President and Mrs. Reagan gathered with their family for a quiet Thanksgiving dinner at their fogbound ranch in the Santa Ynez mountains, where the main topic of conversation was the weather. The Reagans did not seem to mind the enforced seclusion as they sat down to a traditional turkey dinner, prepared by Ann Allman, the Reagan familys longtime cook in California. It was an all-American menu that included cornbread dressing, cranberries, string beans, mashed potatoes, salad, pumpkin pie and monkey bread, a family favorite.

POLL DU JOUR

46% of Americans say long standing family tensions are the cause of family fights during holidays.

37% say general politics is the cause; 33% cite the 2020 presidential race.

24% say someones future plans cause the fights; 24% say money.

22% say the behavior of guests; 21% say drinking and alcohol.

18% say holiday cooking is the cause.

Source: A YouGov poll of 1,310 U.S. Adults conducted Sept. 25-26 and released Tuesday.

Have a happy Thanksgiving and thank you for reading Inside the Beltway.

See more here:
Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table - Washington Times

Skin Stem Cells Comments Off on Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table – Washington Times | November 27th, 2019

Aristotle already observed in the fourth century B.C. that some animals can regrow their tails after losing them, but the mechanisms that support this kind of regeneration remain difficult to understand.

Using single-cell genomics, scientists at the Wellcome Trust / Cancer Research UK Gurdon Institute at the University of Cambridge developed an innovative strategy to show what happens in different tadpole cells when they regenerate their tails.

Recent advances at Cambridge in next-generation single-cell sequencing mean that scientists can now track which genes are turned on throughout a whole organism or tissue, at the resolution of individual cells. This technique, known as single-cell genomics, makes it possible to distinguish between cell types in more detail based on their characteristic selection of active genes.

These groundbreaking discoveries are beginning to reveal a map of cellular identities and lineages, as well as the factors involved in controlling how cells choose between alternative pathways during embryo development to produce the range of cell types in adults.

Using this technology, Can Aztekin and Dr Tom Hiscock under the direction of Dr Jerome Jullien made a detailed analysis of cell types involved in regeneration after damage in African clawed frog tadpoles (Xenopus laevis). Details were published in the journal Science.

Dr Tom Hiscock said: Tadpoles can regenerate their tails throughout their life; but there is a two-day period at a precise stage in development where they lose this ability. We exploited this natural phenomenon to compare the cell types present in tadpoles capable of regeneration and those no longer capable.

The researchers found that the regenerative response of stem cells is orchestrated by a single sub-population of skin cells, which they named Regeneration-Organizing Cells, or ROCs.

Can Aztekin said: Its an astonishing process to watch unfold. After tail amputation, ROCs migrate from the body to the wound and secrete a cocktail of growth factors that coordinate the response of tissue precursor cells. These cells then work together to regenerate a tail of the right size, pattern and cell composition.

In mammals, many tissues such as the skin epidermis, the intestinal epithelium and the blood system, undergo constant turnover through life. Cells lost through exhaustion or damage are replenished by stem cells. However, these specialised cells are usually dedicated to tissue sub-lineages, while the ability to regenerate whole organs and tissues has been lost in all but a minority of tissues such as liver and skin.

Professor Benjamin Simons, a co-author of the study said: Understanding the mechanisms that enable some animals to regenerate whole organs represents a first step in understanding whether a similar phenomenon could be reawakened and harnessed in mammalian tissues, with implications for clinical applications.

This research was funded by the University of Cambridge, the Cambridge Trust andthe Wellcome Trust;and supported by theEuropean Molecular Biology Organization, the Royal Society,theEuropean Molecular Biology Laboratory, and Cancer Research UK.

Source: University of Cambridge Research

Original post:
Scientists find a cell that helps tadpoles tails regrow - Vryheid Herald

Skin Stem Cells Comments Off on Scientists find a cell that helps tadpoles tails regrow – Vryheid Herald | November 27th, 2019

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)

David G. Armstrong, University of Southern California

(THE CONVERSATION) What if someone told you that theres a disease you could catch where you couldnt feel any symptoms coming on? And that this occurs every 1.2 seconds somewhere in the world?

What if you were stricken with this disease then there would be a 5% chance youd lose a limb within a year and a 50-70% chance youd be dead in five years? What if you were told that this problem cost more than the five most expensive cancers in the U.S. but far less than one one-thousandth of comparative federal and private funding is spent on attacking it?

Ladies and gentlemen, please allow me to introduce you to the humble diabetic foot ulcer. While the problem may strike at the end of the body, far away from the heart or the brain, its effects are far-reaching.

I have spent my career treating and researching the lower extremity complications of diabetes. Based on my research and experience, I believe our society could eliminate immeasurable suffering if we collectively paid more attention to this problem.

How do diabetic foot ulcers occur?

OK, I know this isnt a sexy topic. Foot wounds are ugly. Many people who have them are poor. But bear with me. They are a reality for far too many Americans and people across the globe. The ages of these patients are bimodal, in that there is one population of people who are old and getting older. Conversely, with more and more people being diagnosed with Type 2 diabetes earlier, there is a population that is younger than ever being afflicted with wounds, infections and amputation. Ignoring the problem is an example of ignoring the needs of a silent and vulnerable population.

About 31 million people in the U.S. have diabetes, and about half a billion worldwide.

Diabetic foot ulcers develop because people with diabetes slowly lose the gift of pain. Over many years, people with diabetes lose feeling in their extremities. This occurs first and generally most profoundly in their feet.

Once this occurs, people with diabetes might wear a hole in their foot, just as you or I might wear a hole in a sock or shoe. This hole is called a diabetic foot ulcer.

About half the time, the ulcer will become infected. This increases the risk of further tissue damage and, in the face of frequent vascular disease, high-level amputation. Often all of this occurs with few, if any, symptoms until it is too late.

Solutions and hope

There is also good news. Studies have suggested that high-level amputations seem to decrease when interdisciplinary care is in place, regardless of the country.

Interdisciplinary teams consist of podiatric and vascular surgeons, the so-called Toe and Flow model. The concept is simple; these two specialists, can manage a great deal of the medical, surgical and biomechanical aspects of healing and aftercare.

When we add core physical therapy to this, then the threesome (what we in the field call Toe, Flow and Go) is really quite formidable. For example, our clinics at the University of Southern California and Rancho Los Amigos in Los Angeles have active participation from more than eight specialists ranging from plastic surgery to prosthetics/orthotics, to occupational therapy to nutrition to general practice to infectious disease to diabetology to nurse case management.

Truly, it takes a village to preserve a limb.

Smart boots, high-tech vacuums and sheets of stems cells

It has long been said in wound care that its not what one puts on a wound that heals it, but what one takes off. That maxim is absolutely true in the diabetic foot. Protection of the wound is key.

The gold standard for protecting the wound has been, believe it or not, to put the patient into a special cast. This device works so well because it protects the foot in a process known as offloading, or taking the burden off the foot. By its design, this cast is not easy to remove.

While this has been my personal favorite device to heal these foot wounds, patients dont like it and most doctors dont, either. In fact, fewer than 2% of centers in the country use this as their primary means of offloading. Reasons for this include fear of putting an open wound into a cast (even though the data largely refute this), the time required to apply and remove it and patients being miserable in a hot and heavy device.

Very recently, tech company offshoots have begun to partner with prosthetic/orthotic companies to create next-gen devices that can coax patients into wearing their protective device rather than forcing it upon them. They are using phone calls and a smartwatch.

After focusing on offloading pressure, the next question is what can be done to heal the wound.

Technologies ranging from fancy vacuums, to donated placental tissue, to repurposing blood cells into a dressing to topical oxygen systems have shown recent promise. Active research is being conducted with stem cell sheets consisting of specialized cells seeded on a clear sheet, spread-on skin, and gene therapy.

Remission

As challenging as healing the wound heals, the real challenge is whats next. Following healing, 40% of foot wounds will recur in one year, about two-thirds at three years, and nearly three out of four at five years.

At USC, along with colleagues in the National Health Service in the U.K., we have developed remission clinics designed to extend and promote an active life for this high-risk patient population.

This has also been combined with things like smart insoles, socks and home-based bathmats that can identify wounds before they occur. These technologies will likely initially be subscription-based but may expand beyond that.

Diabetic foot ulcers are common, complex and costly. Theyre sinister in that they come on quietly. Perhaps, though, it is now up to us to alert our own families, communities and leaders to this condition. It is, I believe, only by teaming up that we can stem the tide and preserve not only limbs, but extend lifespan, healthspan and hope.

[ Youre smart and curious about the world. So are The Conversations authors and editors. You can read us daily by subscribing to our newsletter. ]

This article is republished from The Conversation under a Creative Commons license. Read the original article here: http://theconversation.com/diabetic-foot-wounds-kill-millions-but-high-tech-solutions-and-teamwork-are-making-a-difference-127218.

See the article here:
Diabetic foot wounds kill millions, but high-tech solutions and teamwork are making a difference - Thehour.com

Skin Stem Cells Comments Off on Diabetic foot wounds kill millions, but high-tech solutions and teamwork are making a difference – Thehour.com | November 27th, 2019

A new study by Rutgers University researchers suggests that two genes expressed in the intestinal cells that line the inside of the colon may also be involved in cancer development.

Recent studies have shown that intestinal stem cells can increase in animals on a high fat Western diet, potentially explaining an elevated cancer risk from such a diet.Diet being able to control cell proliferation is an interesting research development, particularly the convergence of dietary factors and dysregulated gene signaling driving malignant transformations and promoting an adenoma-to-adenocarcinoma progression.

This new study suggests a novel connection between HNF4A and HNF4G genes, diet and cancer.Genetic expression of HNF4 has previously been shown by to be heavily influenced by the gut microbiota, which in turn can influence a multitude of intestinal disorders.

Non-host gene regulation was further explored in this study by using a high fat diet to test how these genes work, and the researchers discovered they help co-regulate stem cell proliferation, as well as help intestine cells burn dietary fat. This was done by isolating cells from knockout and control mice and observing intestine stem cell proliferation under conditions of high fat and control. Mice that had both HNF4A and HNF4G knocked out were unable to have their stem cells proliferate under high fat conditions.

Intestinal stem cells undergo constant renewal and fuel the continuous turnover of the lining of the intestine. People naturally lose millions of intestinal cells daily, much like they lose skin cells. If this rate of replication is not closely controlled, it can quickly lead to malignancy. Lack of proliferation can be very problematic for the colon and damaging to lower layers of cells.

This [research] is important because scientists have shown that when theres too much dietary fat in the intestine, stem cell numbers increase, boosting susceptibility to colon cancer, said senior author Michael Verzi, an associate professor in the Department of Genetics in the School of Arts and Sciences at Rutgers UniversityNew Brunswick.

Rutgers scientists believe HNF4A and HNF4G help stem cells burn fat, providing them energy. By linking gene activation, cell replication number, diet and cancer risk, scientists might be able to better understand the cancer development process in high risk patients. Going forward, the researchers plan to continue studying whether these two genes alter stem cell numbers and cancer risk alongside a high fat diet, said Verzi.

Colorectal cancer (of the colon or rectum) is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, over 100,000 Americans will be diagnosed with colon cancer this year. This cancer is also the second most deadliest in the United States, but due to a combination of increased screening and heightened awareness the death rate has been dropping. However, in patients under the age of 55, the death rate of colon cancer has increased each year by 1% since 2007. Approximately 50,000 colon cancer patients are expected to die in 2019.

Read this article:
New Link Discovered Between Cells That Burn Fat and Colon Cancer - Clinical OMICs News

Skin Stem Cells Comments Off on New Link Discovered Between Cells That Burn Fat and Colon Cancer – Clinical OMICs News | November 27th, 2019

AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, and scientists at the Gates Center for Regenerative Medicine at the University of Colorado School of Medicine have announced a preclinical research collaboration to establish proof-of-concept and explore further development of a spray-on treatment of genetically modified cells for patients with epidermolysis bullosa (EB), with potential applicability to other genetic skin disorders.

The partnership will pair AVITA Medicals patented and proprietary Spray-On Skin Cells technology and expertise with the Gates Centers innovative, patent pending combined reprogramming and gene editing technology to allow cells to function properly. Under the terms of the Sponsored Research Agreement (SRA), AVITA Medical retains the option to exclusively license technologies emerging from the partnership for further development and commercialization. The Gates Center team is further supported by the EB Research Partnership in New York, the Los Angeles-based EB Medical Research Foundation, the London-based Cure EB Charity and government grants, in a collaborative effort to rapidly develop and translate this technology to the clinic for meaningful impact on patient lives.

The Gates Center is a leader in developing therapeutic approaches for genetic skin diseases. Researchers at the Gates Center have developed a powerful new approach for treating genetic skin disorders and improving the lives of patients with epidermolysis bullosa, said Mike Perry, PhD, chief executive officer of AVITA Medical and adjunct professor at the Gates Center for Regenerative Medicine. We look forward to collaborating with the team at the Gates Center on the expanded use of our technology. This agreement marks an important milestone in AVITAs mission to harness the potential of regenerative medicine to address unmet medical needs across a broad range of dermatological indications, including genetic disorders of the skin.

Epidermolysis bullosa is a group of rare and incurable skin disorders caused by mutations in genes encoding structural proteins resulting in skin fragility and blistering, leading to chronic wounds and, in some sub-types, an increased risk of squamous cell carcinoma or death. There are no approved curative therapies, and current treatment is palliative - focused primarily on pain and nutritional management, itching relief, wound care, and bandaging.

Its very exciting to partner with AVITA Medical to help advance our epidermolysis bullosa program, said Director of the Gates Center for Regenerative Medicine Dennis Roop, PhD. Were looking forward to exploring a novel approach to delivering gene-edited skin cells to patients that addresses current treatment challenges.

We believe that Spray-On Skin Cells technology combined with our genetically corrected cells has the potential to be game changing in the treatment of this disease. This combination could reduce time to treatment, lower manufacturing complexity, reduce costs and improve patient outcomes, said Ganna Bilousova, PhD, assistant professor of dermatology, who is a co-principal investigator on this research program.

ABOUT THE CHARLES C. GATES CENTER FOR REGENERATIVE MEDICINE

The Charles C. Gates Center for Regenerative Medicine was established in 2006 with a gift in memory of Denver industrialist and philanthropist, Charles C. Gates, who was captivated by the hope and benefit stem cell research promised for so many people in the world. The Gates Center aspires to honor what he envisionedby doing everything possible to support the collaboration between basic scientific researchers and clinical faculty to transition scientific breakthroughs into clinical practice as quickly as possible.

Led by Founding Director Dennis Roop, PhD, the Gates Center is located at the University of Colorados Anschutz Medical Campus, the largest new biomedical and clinical campus in the United States. Operating as the only comprehensive Stem Cell Center within a 500-mile radius, the Gates Center shares its services and resources with an ever-enlarging membership of researchers and clinicians at the Anschutz Medical Campus, which includes University of Colorado Hospital, Childrens Hospital Colorado and the Veterans Administration Medical Center, as well as the Boulder campus, Colorado State University, the Colorado School of Mines, and business startups. This collaboration is designed to draw on the widest possible array of scientific exploration relevant to stem cell technology focused on the delivery of innovative therapies in Colorado and beyond.

ABOUT THE UNIVERSITY OF COLORADO SCHOOL OF MEDICINE

Faculty at the University of Colorado School of Medicine work to advance science and improve care. These faculty members include physicians, educators and scientists at University of Colorado Hospital, Childrens Hospital Colorado, Denver Health, National Jewish Health, and the Denver Veterans Affairs Medical Center. The school is located on the CU Anschutz Medical Campus, one of four campuses in the University of Colorado system. To learn more about the medical schools care, education, research and community engagement, visit its web site.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION (RES), an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. Burn Centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit http://www.avitamedical.com.

Photo at top: From left, Igor Kogut, PhD, Ganna Bilousova, PhD, and Dennis Roop, PhD.

Guest contributor: Gates Center for Regenerative Medicine/ASX

View post:
AVITA Medical Teams With Gates Center to Advance Therapeutic Skin Restoration - CU Anschutz Today

Skin Stem Cells Comments Off on AVITA Medical Teams With Gates Center to Advance Therapeutic Skin Restoration – CU Anschutz Today | November 26th, 2019

When it comes to our beauty and skincare products, it's easy for years to pass without an updateor even an upgrade. But because advances in beauty technology are happening at the speed of light, its always important to pause and reassesswhat we're usingfrom dog shampoo to stem-cell skincare. SoI've rounded up the best of the latest trends that have earned a place inmymakeup bag.

Its no secret that Ima major fan of Kjaer Weisthere is something utterly fresh and clean about everything for the face and body, and its as organic as it can get. Enter the latest additions to the line: the cleanser ($95) and toner ($85, both pictured above). Not only does the soft, gel-like cleanser effectively remove all makeup, but its also calming. Follow it with a quick spritz of the toner and you have hydrated and re-balanced skin. Plus, the scents aredreamy.If I could accurately describe them, I would. But I was in Bluemercury downtown recently they have sample bottles to give it a go yourself.Bluemercury, 1500 Main Street, Sarasota. (941) 365-0020

Two things on my must-do-better list: Sunscreen and preventing this neck from aging. Addressing the first, Alastin Skincares HydraTint Pro Mineral Sunscreen SPF 36 ($55) is a revelation. Not only is it lightweight, with broad-spectrum UVA/UVB sun protection, it also protects against environmental pollution and it has a universal tint that enhances most skin tones. Its the first thing Iput on in the morning before taking the dogs for a walk; I love the just-right tinted coverage.

Second, that neck thing. As much as I prefer organic and natural skincarewhen possible, I tend to lean on science for combatting aging. Enter: Nectifirm Advanced ($133). Its next-gen technology based on the ecosystem of the skins microbiome, plus eight peptides that helps skin appear firmer and lifted while lessening the appearance of lines and wrinkles. Not to mention that those in the know at Sarasota Facial Aesthetics rave about the results. Get both products atSarasota Facial Aesthetics, 1445 South Osprey Ave., Suite 2, (941) 955-8384.

I was of the mind that a razor is a razoris a razor. Well, thats changed since theFlamingo razor($9.99) came on my radar. The team raised the bar on shaving after spending years talking to women (what a concept!) who shared the nuances of their personal care rituals and how typical razors fell short. Use this once and it will be clear that they did not overlook those edges of our bodies that need extra attention.Target, 101 N. Cattlemen Road, (941) 360-7520

Speaking of: here's another kind of sunscreen, this time for the eye area. Who knew? I recently discovered Colorescience Total Eye3-in-1 Renewal Therapy SPF 35 ($74)they say it visibly improves the appearance of dark circles, puffiness, fine lines and wrinkles, while protecting the delicate eye area against photoaging with 100 percent SPF 35 mineral sunscreen. I say its great coverage, and if it comes with all of those benefits then...yay!L. Spa, 556 Pineapple Ave., (941) 906-1358

Brace yourself (and maybe your credit card) because Augustinus Baders The Cream ($265) is right there at the cutting edge for stem cell skincare. Get this: the stem cells found in skin lie dormant, awaiting an activation signal to repair the damage inflicted by life and environmental factors.The patented technology TFC8Bader's proprietary "Trigger Factor Complex"is comprised of natural amino acids, high-grade vitamins and synthesized molecules that are found naturally in the skin. Its a repairing force in an ultra-lightweight cream that guides key nutrients and powerful natural ingredients to the skin cells, creating an optimal environment for the body's innate processes of repair and renewal.Thats a lot, but all I know is that I can see the results after a lotta life has happened to my skin. Its crazy good, and I guess for the price it should be. Saks Fifth Avenue, 120 University Town Center Drive, Sarasota. (941) 364-5300

Lastly, this one is for the love of our fur kids, especially those with sensitive skin. The Malin + Goetz Dog Shampoo ($28) is infused with natural botanical amino acids to gently cleanse fur and skin without drying, stripping or irritating. And I can attest that fur dries soft and oh-so-shiny. Malin + Goetz, malinandgoetz.com

Excerpt from:
Seven Products Our Beauty Editor Used to the Last Drop - Sarasota

Skin Stem Cells Comments Off on Seven Products Our Beauty Editor Used to the Last Drop – Sarasota | November 26th, 2019

Nov. 24, 2019 23:45 UTC

VALENCIA, Calif., MELBOURNE, Australia & AURORA, Colo.--(BUSINESS WIRE)-- AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, and scientists at the Gates Center for Regenerative Medicine at the University of Colorado School of Medicine announced today a preclinical research collaboration to establish proof-of-concept and explore further development of a spray-on treatment of genetically modified cells for patients with epidermolysis bullosa (EB), with potential applicability to other genetic skin disorders.

The partnership will pair AVITA Medicals patented and proprietary Spray-On Skin Cells technology and expertise with the Gates Centers innovative, patent-pending combined reprogramming and gene-editing technology to allow cells to function properly. Under the terms of the Sponsored Research Agreement (SRA), AVITA Medical retains the option to exclusively license technologies emerging from the partnership for further development and commercialization. The Gates Center team is further supported by the EB Research Partnership in New York, the Los Angeles-based EB Medical Research Foundation, the London-based Cure EB Charity, and government grants in a collaborative effort to rapidly develop and translate this technology to the clinic for meaningful impact on patient lives.

The Gates Center is a leader in developing therapeutic approaches for genetic skin diseases. Researchers at the Gates Center have developed a powerful new approach for treating genetic skin disorders and improving the lives of patients with epidermolysis bullosa, said Dr. Mike Perry, Chief Executive Officer of AVITA Medical and adjunct professor at the Gates Center for Regenerative Medicine. We look forward to collaborating with the team at the Gates Center on the expanded use of our technology. This agreement marks an important milestone in AVITAs mission to harness the potential of regenerative medicine to address unmet medical needs across a broad range of dermatological indications, including genetic disorders of the skin.

Epidermolysis bullosa is a group of rare and incurable skin disorders caused by mutations in genes encoding structural proteins resulting in skin fragility and blistering, leading to chronic wounds and, in some sub-types, an increased risk of squamous cell carcinoma or death. There are no approved curative therapies, and current treatment is palliativefocused primarily on pain and nutritional management, itching relief, wound care, and bandaging.

Its very exciting to partner with AVITA Medical to help advance our epidermolysis bullosa program, said Director of the Gates Center for Regenerative Medicine Dr. Dennis Roop. Were looking forward to exploring a novel approach to delivering gene-edited skin cells to patients that addresses current treatment challenges.

We believe that Spray-On Skin Cells technology combined with our genetically corrected cells has the potential to be game changing in the treatment of this disease. This combination could reduce time to treatment, lower manufacturing complexity, reduce costs, and improve patient outcomes, said Dr. Ganna Bilousova, assistant professor of dermatology, who is a co-principal investigator on this research program.

ABOUT THE CHARLES C. GATES CENTER FOR REGENERATIVE MEDICINE

The Charles C. Gates Center for Regenerative Medicine was established in 2006 with a gift in memory of Denver industrialist and philanthropist Charles C. Gates, who was captivated by the hope and benefit stem cell research promised for so many people in the world. The Gates Center aspires to honor what he envisionedby doing everything possible to support the collaboration between basic scientific researchers and clinical faculty to transition scientific breakthroughs into clinical practice as quickly as possible.

Led by Founding Director Dennis Roop, Ph.D., the Gates Center is located at the University of Colorados Anschutz Medical Campus, the largest new biomedical and clinical campus in the United States. Operating as the only comprehensive Stem Cell Center within a 500-mile radius, the Gates Center shares its services and resources with an ever-enlarging membership of researchers and clinicians at the Anschutz Medical Campus, which includes University of Colorado Hospital, Childrens Hospital Colorado, and the Veterans Administration Medical Center, as well as the Boulder campus, Colorado State University, the Colorado School of Mines, and business startups. This collaboration is designed to draw on the widest possible array of scientific exploration relevant to stem cell technology focused on the delivery of innovative therapies in Colorado and beyond.

ABOUT THE UNIVERSITY OF COLORADO SCHOOL OF MEDICINE

Faculty at the University of Colorado School of Medicine work to advance science and improve care. These faculty members include physicians, educators, and scientists at University of Colorado Hospital, Childrens Hospital Colorado, Denver Health, National Jewish Health, and the Denver Veterans Affairs Medical Center. The school is located on the Anschutz Medical Campus, one of four campuses in the University of Colorado system. To learn more about the medical schools care, education, research, and community engagement, visit its web site.

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION (RES), an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. Burn Centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information, including contraindications, warnings, and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications, including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.

To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191124005098/en/

More here:
AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore...

Skin Stem Cells Comments Off on AVITA Medical and the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus Enter into Collaboration to Explore… | November 26th, 2019

Over lunch at the Canadian Centre for Alternatives to Animal Methods (CCAAM), Charu Chandrasekera nonchalantly mentions one of the projects her team is working on. We are just printing some human liver tissue right now, she says.

Chandrasekera launched the CCAAM at the University of Windsor in 2017, with help from the schools vice-president of research and innovation, Michael Siu, and dean of science, Chris Houser. The centre promotes non-animal methods in biomedical research, education, and regulatory (chemical safety) testing. In October 2019, the centre received a million-dollar gift from the Eric S. Margolis Family Foundation, which Chandrasekera says was instrumental in establishing the state-of-the art research laboratory, and in launching a number of important initiatives.

Chandrasekera says the move away from animal testing to human-based research models isnt radical but inevitable. After many years working in biomedical research with mouse models of heart disease and diabetes, It became very obvious that the work I was doing was not translatable [to humans], she says. Nothing was really reproducible; there were so many discrepancies and contradictions, even among the top-notch researchers.

Ninety-five per cent of drugs tested to be safe and effective in animal models fail in human clinical trials, says Chandrasekera. Alzheimers disease99.6 per cent drug failure rate, she says. It has been cured in mice. But we dont even understand the molecular mechanisms of this disease in humans, much less a cure.

RELATED:I am mine: This is what Alzheimers is like at 41

Empirical evidence from across a whole host of biomedical science disciplines shows us that animal models are failing both science and human health, echoes Elisabeth Ormandy, co-founder and executive director of Animals in Science Policy Institute, a registered Canadian charity working to promote better science without animals. Animal models can falsely show that a drug is effective, she says. They can also falsely show no effect, in which case a drug that would have been shown to be effective in humans never gets advanced to human clinical trials.

The result, she says, is billions of public tax dollars being wasted on research using ineffective animal models, and diversion of precious research funding away from other lines of scientific inquiry that might hold greater promise in terms of predicting drug safety, risk, and effectiveness.

Those other promising lines of scientific inquiry, say Ormandy and Chandrasekera, are human biology-based models. We can use human cells and tissues from cadavers, biopsies, and explanted organs [from surgeries], says Chandrasekera. And we can also engineer them. With adult stem cell technology, you can take a small biopsylike two-to-three millimetres from a persons skinto create any cell type in your body, she says. And if that person has a disease, such as Alzheimers, it will still be present in these cells. These cells can then be assembled to form tissue-like structures called organoids, or engineered through 3D-bioprinting to create more complex tissues, all of which can be combined to create what has become known as disease-in-a-dish. At present,Chandrasekera iscreating diabetes-in-a-dish.

Further, those cells and tissues can also be placed onto computer chips the size of thumb drives, where a large number of drugs can be tested to select whats most appropriate for youpersonalized medicine based on your cells, your tissues, your biologynot mouse biology, Chandrasekera explained in her April 2019 TedX Talk. The goal of the scientific community at large is to create a human-on-a-chip to emulate human biology better than animals, she says, which I think will happen over the next decade.

Currently there is no data on the success rates of human biology-based methods, because there are no drugs that have been approved without animal testing, since animal testing was mandated by regulatory guidelines several decades ago, says Chandrasekera.

However, a growing body of scientific data and internationally approved guidelines in chemical safety testing, indicate that alternative methods are equal or superior to animal models in predicting human biology, Chandrasekera says. Even computer simulations are out-predicting animal-derived data.

RELATED:Health care cannot modernize unless health policy changes first

Ifdisease-in-a-dish and toxicity-on-a-chip effortscontinue to advance at a fast pace with a sense of urgencybacked by global scientific, financial, legislative, and ethical mandates, she says, we will come to a point where we can test drugs without relying on animals.

And while Chandrasekera is busy both in the lab and on the global stage promoting her work, she is also focused on enlightening future scientists. Shes working the development of courses and degrees to train the next generation, she says, to think outside the cage.

Continued here:
Hatching disease in a dish: The new frontier in drug testing - Maclean's

Skin Stem Cells Comments Off on Hatching disease in a dish: The new frontier in drug testing – Maclean’s | November 26th, 2019

The 88-year-old actor known for his role as Captian James T. Kirk on the popular cinema and television series Star Trek, William Shatner recently Tweeted, Today I received restorative stem cells and told his followers Is it possible to turn back the clock? I will let you know.Mr. Shatner also tweeted the Stem Cells are manufactured by Invitrx.Center for Regenerative Medicine & Stem Cell Therapy at Valencia Medical Center is a pioneer in stem cell regenerative medicine in Santa Clarita Valley has been producing PRP and stem cell treatments for cosmetic treatments for cosmetic rejuvenation, hair restoration and chronic knee pain due to arthritis knee meniscus injury, cartilage, ligaments (ACL, MCL), osteoarthritis treatment. Invitrx, a California native is a global research-based company in regenerative medicine and is a major source of stem cell products for Valencia Medical Center.Non-surgical regenerative cell-based treatment uses the bodys natural healing ability to repair damaged bones, muscles, cartilage, tendons and ligaments. Knee injuries are painful and often patients are unable to walk. Our treatment protocol always uses products following FDA guidelines. Injections done with ultrasound guided needle recognition capability to ensure safety as well target the area needing treatment. Plasma; Alpha-2-Macroglobulim (A2M) is the new biologic treatment for your arthritic knee (osteoarthritis)When your hips hurt, or your knee is stiff, or your back is throbbing, that means your joint is bone on bone and there is no lubrication to ease movement.Regenerative medicine giving new hope to patients suffering from painful joint injuries such as knee, shoulder and hip with a chance to live a pain free life.Regenerative cell-based ultrasound guided injection now available to treat pain associated with joint injury. There are indications that it reduces the pain and swelling of the joints and helps lubricating and improve movements.Commonly Treated Conditions: Osteoarthritis of the Hips, Knee, and Shoulders Rotator Cuff tears of the Shoulder Meniscus, ACL and PCL tears of the kneeOur stem cell treatment using your own stem cells and with using imaging guidance ensures precise injection of stem cell, it is a highly-specialized practice.Besides treating above injuries we have advance stem cell micro-needling treatment for the following: Cell-based PRP Hair Restoration combining micro-needling with growth factors and hair follicles voluma vitamins plus BLotinyl T1, Biotin, Anti-aging and Kopexil. Non-toxin facial renewal Anti-Aging APGF Advanced Peptide Micro-needling PRP, Dual Anti-Aging Ampoules for deep hydration, more collagen to reduce wrinkles and firm skin.Dr. Ibrahim is the staff physician at Valencia Medical Center specializing in regenerative medicine, pain management, and rejuvenation. Call for a consultation at 661-222-9117.

View post:
Star Trek's William Shatner Receives Stem Cell Treatment to Restore his Youth - Magazine of Santa Clarita

Skin Stem Cells Comments Off on Star Trek’s William Shatner Receives Stem Cell Treatment to Restore his Youth – Magazine of Santa Clarita | November 26th, 2019